InvestorsObserver
×
News Home

Do Analysts Expect Seelos Therapeutics Inc (SEEL) Stock to Rise After It Has Fallen -6.36% in a Month?

Thursday, December 30, 2021 11:47 AM | InvestorsObserver Analysts

Mentioned in this article

Do Analysts Expect Seelos Therapeutics Inc (SEEL) Stock to Rise After It Has Fallen -6.36% in a Month?

Wall Street is positive on Seelos Therapeutics Inc (SEEL). On average, analysts give Seelos Therapeutics Inc a Strong Buy rating. The average price target is $9.5, which means analysts expect the stock to gain by 486.42% over the next twelve months. That average ranking earns Seelos Therapeutics Inc an Analyst Rating of 74, which is better than 74% of stocks based on data compiled by InvestorsObserver.

Overall Score - 5
Wall Street analysts are rating SEEL a Strong Buy today. Find out what this means to you and get the rest of the rankings on SEEL!

Why are Analyst Ratings Important?

Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve. InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.

What's Happening With Seelos Therapeutics Inc Stock Today?

Seelos Therapeutics Inc (SEEL) stock has fallen -2.96% while the S&P 500 is higher by 0.13% as of 11:46 AM on Thursday, Dec 30. SEEL is down -$0.05 from the previous closing price of $1.67 on volume of 769,325 shares. Over the past year the S&P 500 has gained 28.60% while SEEL is higher by 4.52%. SEEL lost -$0.60 per share the over the last 12 months. Click Here to get the full Stock Report for Seelos Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App